{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:23:45Z","timestamp":1705105425896},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1986,3,1]],"date-time":"1986-03-01T00:00:00Z","timestamp":510019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1986,3,1]],"date-time":"1986-03-01T00:00:00Z","timestamp":510019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1986,3]]},"DOI":"10.1007\/bf00172013","type":"journal-article","created":{"date-parts":[[2004,8,15]],"date-time":"2004-08-15T08:39:12Z","timestamp":1092559152000},"page":"31-38","source":"Crossref","is-referenced-by-count":5,"title":["Phase I study of oral idarubicin given with a weekly schedule"],"prefix":"10.1007","volume":"4","author":[{"given":"P.","family":"Dodion","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Finet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Crespeigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Nicaise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rozencweig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Kenis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00172013_CR1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJM198107163050305","volume":"305","author":"RC Young","year":"1981","unstructured":"Young RC, Ozols RF, Myers CE: The anthracycline antineoplastic drugs. N Engl J Med 305:139\u2013153, 1981","journal-title":"N Engl J Med"},{"key":"BF00172013_CR2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Von Hoff","year":"1979","unstructured":"Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710\u2013717, 1979","journal-title":"Ann Intern Med"},{"key":"BF00172013_CR3","first-page":"549","volume":"60","author":"F Arcamone","year":"1980","unstructured":"Arcamone F, Bernardi L, Giardino P, Patelli B, Di Marco A, Casazza AM, Pratesi G, Reggiani P: Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-deme-thoxy-7,9-diepidaunorubicin, and their beta anomers. Cancer Treat Rep 60:549\u2013564, 1980","journal-title":"Cancer Treat Rep"},{"key":"BF00172013_CR4","first-page":"829","volume":"66","author":"AM Casazza","year":"1976","unstructured":"Casazza AM, Pratesi G, Giuliani F, Di Marco A: Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori 66:829\u2013834, 1976","journal-title":"Tumori"},{"key":"BF00172013_CR5","unstructured":"Sviluppo RE: IMI30. 4-demethoxydaunorubicin. Farmitalia Carlo Erba Clinical Brochure, 1980"},{"key":"BF00172013_CR6","first-page":"835","volume":"63","author":"AM Casazza","year":"1979","unstructured":"Casazza AM: Experimental evaluation of anthracycline analogs. Cancer Treat Rep 63:835\u2013844, 1979","journal-title":"Cancer Treat Rep"},{"key":"BF00172013_CR7","first-page":"6096","volume":"43","author":"E Berman","year":"1983","unstructured":"Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Williams L, Baratz R, Young CW: Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Cancer Res 43:6096\u20136101, 1983","journal-title":"Cancer Res"},{"key":"BF00172013_CR8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00172075","volume":"1","author":"V Bonfante","year":"1983","unstructured":"Bonfante V, Ferrari L, Villani F, Bonadonna G: Phase I study of 4-demethoxydaunorubicin. Invest N Drugs 1:161\u2013168, 1983","journal-title":"Invest N Drugs"},{"key":"BF00172013_CR9","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0277-5379(82)90133-X","volume":"18","author":"S Kaplan","year":"1982","unstructured":"Kaplan S, Martini A, Varini M, Togni P, Cavalli F: Phase I trial of 4-demethoxydaunorubicin with single iv doses. Eur J Cancer Clin Oncol 18:1303\u20131306, 1982","journal-title":"Eur J Cancer Clin Oncol"},{"key":"BF00172013_CR10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00175378","volume":"2","author":"S Kaplan","year":"1984","unstructured":"Kaplan S, Willems Y, Sessa C, Pacciarini MA, Tamassia V, Cavalli F: Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses. Invest N Drugs 2:281\u2013286, 1984","journal-title":"Invest N Drugs"},{"key":"BF00172013_CR11","first-page":"181","volume":"2","author":"A Daghestani","year":"1983","unstructured":"Daghestani A, Arlin ZA, Gee TS, Kempin S, Mertelsmann R, Budman D, Schulman P, Cassidy C, Raymond V, Clarkson BD, Young CW: Treatment of acute leukemia in relapse with 4-demethoxydaunorubicin. Proc Am Soc Clin Oncol 2:181, 1983","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF00172013_CR12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.7326\/0003-4819-99-6-745","volume":"99","author":"MT Torti","year":"1983","unstructured":"Torti MT, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW, Billingham ME: Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Ann Intern Med 99:745\u2013749, 1983","journal-title":"Ann Intern Med"},{"key":"BF00172013_CR13","volume-title":"Handbook for reporting results of cancer treatment","author":"WHO","year":"1979","unstructured":"WHO Handbook for reporting results of cancer treatment. WHO, Geneva, 1979"},{"key":"BF00172013_CR14","first-page":"201","volume":"25","author":"M Rozencweig","year":"1984","unstructured":"Rozencweig M, Crespeigne N, Nicaise C, Gerard B, Atassi G, Tagnon H, Kenis Y: Phase I trial of 1,2,4-triglycidylurazol (TGU, NSC 332488) with a daily x 5 schedule. Proc Am Assoc Cancer Res 25:201, 1984","journal-title":"Proc Am Assoc Cancer Res"},{"key":"BF00172013_CR15","first-page":"119","volume":"2","author":"P Dodion","year":"1984","unstructured":"Dodion P, Davis TA, Rozencweig M, Watthieu M, Crespeigne N, Beer M, Bachur NR: Human pharmacokinetics of 4-demethoxydaunorubicin. Invest N Drugs 2:119, 1984","journal-title":"Invest N Drugs"},{"key":"BF00172013_CR16","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/0277-5379(83)90078-0","volume":"19","author":"P Dodion","year":"1983","unstructured":"Dodion P: Clinical pharmacology in oncology. Recent advances. Eur J Cancer Clin Oncol 19:1499\u20131507, 1983","journal-title":"Eur J Cancer Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00172013\/fulltext.html","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00172013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00172013\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00172013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00172013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:31:10Z","timestamp":1678559470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00172013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986,3]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1986,3]]}},"alternative-id":["BF00172013"],"URL":"https:\/\/doi.org\/10.1007\/bf00172013","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986,3]]}}}